We are thrilled to share that Biocytogen will exhibit at Advanced Therapies from November 4th - 5th in Boston, MA. Our team will be at booth #323, showcasing our AI-powered antibody discovery platform, RenTCR TCR discovery capabilities and target-humanized mouse models supporting next-generation cell and gene therapies, from therapeutic discovery to in vivo evaluation.
What is Advanced Therapies?
The Advanced Therapies Congress brings together leaders in biotechnology, pharmaceutical research, and healthcare to address cell and gene therapy development challenges and advance patient care. The 12-track agenda will span the full value chain of therapeutics development. Attendees can explore emerging technologies, the latest research findings, and learn more about the strategies that are driving the future of the industry.
Event Overview
Date: November 4th - 5th, 2026
Venue: Hynes Convention Center, 900 Boylston St, Boston, MA 02115
Booth: 323
Poster
Dual Humanized TFR1 and CD98HC Mouse Model Enables Robust Validation and Pharmacokinetic Assessment of BBB-Targeted Biologics
The RenTCR Platform Identifies Potent HLA-A*02:01- and HLA-A*24:02-Restricted PRAME-Specific TCRs with Antitumor Activity
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
